Source:http://linkedlifedata.com/resource/pubmed/id/12637317
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2003-6-19
|
pubmed:abstractText |
Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronic-phase CML after failure on interferon-alpha were treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 months (range, 10-135 months); 4 patients (11%) had clonal evolution. All 11 patients with active disease achieved complete hematologic response. Excluding patients with fewer than 35% Ph-positive metaphases before the start of therapy, 19 (90%) of 21 evaluable patients achieved a major cytogenetic response. Of 27 evaluable patients, 24 (89%) achieved a complete cytogenetic response. Quantitative polymerase chain reaction was performed in bone marrow every 3 months. Of 32 evaluable patients, 18 (56%) showed BCR-ABL/ABL percentage ratios lower than 0.045%, including 13 (41%) with undetectable levels. With a median follow-up of 15 months, all patients were alive in chronic phase. Toxicities were similar to those reported with standard dose; 71% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induces complete cytogenetic responses in most patients with chronic-phase CML after interferon failure. This is accompanied by a high rate of molecular remission.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Fusion Proteins, bcr-abl,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidines,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/imatinib
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0006-4971
|
pubmed:author |
pubmed-author:CortesJorgeJ,
pubmed-author:FaderlStefanS,
pubmed-author:FerrajoliAlessandraA,
pubmed-author:FreireichEmil JEJ,
pubmed-author:Garcia-ManeroGuillermoG,
pubmed-author:GilesFrancisF,
pubmed-author:KantarjianHagopH,
pubmed-author:O'BrienSusanS,
pubmed-author:RiosMary BethMB,
pubmed-author:TalpazMosheM,
pubmed-author:ThomasDeborahD,
pubmed-author:VerstovsekSrdanS
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
102
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
83-6
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12637317-Adult,
pubmed-meshheading:12637317-Aged,
pubmed-meshheading:12637317-Cytogenetic Analysis,
pubmed-meshheading:12637317-Female,
pubmed-meshheading:12637317-Fusion Proteins, bcr-abl,
pubmed-meshheading:12637317-Humans,
pubmed-meshheading:12637317-Interferon-alpha,
pubmed-meshheading:12637317-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:12637317-Male,
pubmed-meshheading:12637317-Middle Aged,
pubmed-meshheading:12637317-Piperazines,
pubmed-meshheading:12637317-Pyrimidines,
pubmed-meshheading:12637317-RNA, Neoplasm,
pubmed-meshheading:12637317-Remission Induction,
pubmed-meshheading:12637317-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:12637317-Salvage Therapy
|
pubmed:year |
2003
|
pubmed:articleTitle |
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
|
pubmed:affiliation |
Department of Leukemia and Bioimmunotherapy, M. D. Anderson Cancer Center, University of Texas-Houston, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA. jcortes@mdanderson.org
|
pubmed:publicationType |
Journal Article
|